文献速递血栓与止血

胎儿和新生儿同种免疫性血小板减少症中的HPA-1a抗体不能区分αvβ3与αIIbβ3,且与失活整合素的结合强于活化整合素

HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins.
PubMed 文献 · Blood · 2025-01-01

该研究回顾性和前瞻性收集重症与轻症胎儿和新生儿同种免疫性血小板减少症(FNAIT)孕妇血清,分析抗HPA-1a抗体对αIIbβ3和αvβ3的反应性。疾病严重程度与血小板减少程度及抗HPA-1a抗体对αIIbβ3和αvβ3的高反应性相关,未发现仅与αvβ3或内皮细胞反应的抗体;所有抗体均与血小板和内皮细胞反应,且对αIIbβ3反应 generally 更强。整合素构象和活化状态影响HPA-1a表位可及性和抗体结合;整合素构象活化后,抗HPA-1a抗体对αIIbβ3相对于αvβ3的更高反应性减弱。

要点

  • 重症FNAIT与血小板减少程度及抗HPA-1a抗体对αIIbβ3和αvβ3的高反应性相关。
  • 未发现仅与αvβ3或内皮细胞反应的抗HPA-1a抗体。
  • 所有抗HPA-1a抗体均与血小板和内皮细胞反应,且 generally 对αIIbβ3反应更强。

核心结论

  • 抗HPA-1a抗体不能区分αvβ3与αIIbβ3,且与失活整合素的结合强于活化整合素。
  • 疾病严重程度与血小板减少程度及抗HPA-1a抗体对αIIbβ3和αvβ3的高反应性相关。
  • 数据强调需进一步研究抗HPA-1a抗体内皮特性与FNAIT疾病结局的关系。

研究设计与样本

  • 分析回顾性和前瞻性收集的重症与轻症FNAIT病例孕妇血清大型队列。

主要发现

  • 疾病严重程度与血小板减少程度及抗HPA-1a抗体对αIIbβ3和αvβ3的高反应性相关。
  • 未发现仅与αvβ3或内皮细胞反应的抗HPA-1a抗体。
  • 所有抗HPA-1a抗体均与血小板和内皮细胞反应,并与αvβ3和αIIbβ3转导细胞反应,但 generally 更多与αIIbβ3整合素反应。
  • HPA-1a表位可及性和抗体结合受整合素构象和活化状态影响。
  • 整合素构象活化后,抗HPA-1a抗体对αIIbβ3相对于αvβ3的更高反应性减弱。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步研究抗HPA-1a抗体内皮特性与FNAIT疾病结局的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare but life-threatening condition in which maternal alloantibodies, generated during pregnancy, target human platelet antigens (HPAs), leading to thrombocytopenia and increased risk of bleedings in the fetus or neonate. The most clinically relevant antigen in people of European descent is HPA-1a, located on the integrin β3 subunit. The β3 integrins are conformationally regulated heterodimeric receptors including platelet integrin αIIbβ3 but also αvβ3, expressed strongly on endothelial cells. FNAIT is clinically highly heterogeneous, with symptoms ranging from mild thrombocytopenia to intracranial hemorrhage (ICH), which can cause lifelong disabilities or perinatal death. It has been suggested that anti-HPA-1a antibodies that exclusively react with αvβ3 cause ICH, due to induction of endothelial cell damage and/or defects in angiogenesis. Here, we analyzed a large cohort of retrospectively and prospectively collected maternal sera from severe and mild FNAIT cases. Disease severity was associated with the extent of thrombocytopenia, and with high anti-HPA-1a antibody reactivity toward both αIIbβ3 and αvβ3. Exclusive anti-HPA-1a reactivity with αvβ3 or endothelial cells was not found. In contrast, all anti-HPA-1a antibodies reacted with platelets and endothelial cells, and with αvβ3- and αIIbβ3-transduced cells, but reacted generally more with the αIIbβ3 integrin. Furthermore, HPA-1a epitope accessibility and antibody binding is influenced by integrin conformation and activation status. Higher reactivity of anti-HPA-1a antibodies with αIIbβ3 over αvβ3 diminishes upon integrin conformational activation. Together, these data emphasize the need for further investigation into the relation between endothelial properties of anti-HPA-1a antibodies and disease outcome in FNAIT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Oosterhoff JJ, Stam W, van Brummelen SR, et al. HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins. Blood. 2025. PMID: 40789019. doi:10.1182/blood.2025029618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。